A Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer
A Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer
The purpose of this study is to evaluate the biological effects of abemaciclib in combination
 with anastrozole and compare those to the effects of abemaciclib alone and anastrozole alone
 in the tumors of postmenopausal women with hormone receptor positive (HR+), human epidermal
 growth factor receptor 2 (HER2) negative breast cancer.
Inclusion Criteria:

 -  Have postmenopausal status.

 -  Adenocarcinoma of the breast.

 -  Breast tumor ≥1 centimeter (cm) in diameter, HR+, HER2-.

 -  Neoadjuvant endocrine monotherapy is deemed to be a suitable therapy.

 -  Primary breast cancer that is suitable for baseline core biopsy.

 -  Have adequate organ function.

 Exclusion Criteria:

 -  Bilateral invasive breast cancer.

 -  Metastatic breast cancer (local spread to axillary lymph nodes is permitted).

 -  Inflammatory breast cancer.

 -  Prior systemic therapy or radiotherapy for invasive or non-invasive breast cancer in
 the same breast as currently being treated.

 -  Prior radiotherapy to the ipsilateral chest wall for any malignancy.

 -  Prior anti-estrogen therapy.